Ginkgo Bioworks Holdings, Inc. Overview
Pro stress-test →Ginkgo Bioworks develops a platform for cell programming, operating through Cell Engineering and Biosecurity segments that offer cell engineering research and development solutions, cell engineering tools, artificial intelligence models, and reconfigurable automation systems for biological research and commercialization. The company is focusing on autonomous labs, which are expected to transform biotechnology by integrating robotics and AI.
Strategic Profile
Pro stress-test →Ginkgo plans to divest its biosecurity business to focus investments on autonomous labs, allowing for more targeted growth. The company has significantly reduced its cash burn by 55% in 2025 and secured a $47 million deal with Pacific Northwest National Labs, showcasing interest from federal entities in autonomous labs.
Competitive Landscape
Pro stress-test →Ginkgo provides cell programming services across diverse markets including food, agriculture, pharmaceuticals, and industrial chemicals. Key competitors in synthetic biology and bioengineering include other cell engineering and automation platform providers, though the autonomous lab market remains nascent with limited direct competitors at Ginkgo's integration level.
Industry Context
Ginkgo Bioworks Holdings, Inc. operates in Synthetic Biology / Bioengineering / Laboratory Automation.
Key facts
Founded: 2008 · Headquarters: Boston, MA · Employees: 834 · Revenue: $33M (Q4 2025) · Market cap: $538M